All Updates

All Updates

icon
Filter
Partnerships
Moderna and ElevateBio’s Life Edit Therapeutics sign gene-editing deal
Human Gene Editing
Feb 22, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Human Gene Editing

Human Gene Editing

Feb 22, 2023

Moderna and ElevateBio’s Life Edit Therapeutics sign gene-editing deal

Partnerships

  • Biotechnology company, Moderna Therapeutics, has entered a strategic R&D collaboration with ElevateBio’s wholly-owned gene-editing subsidiary, Life Edit Therapeutics, to identify and develop novel gene-editing-based therapeutics for genetic and other diseases. 

  • Life Edit will be eligible to receive an upfront payment together with milestone and royalty payments from Moderna. The detailed terms and financial details of the partnership were not disclosed.

  • The partnership will leverage Life Edit’s proprietary gene-editing technologies, such as base editing and Moderna’s messenger ribonucleic acid (mRNA) platform, to develop novel in-vivo treatments for a number of undisclosed therapeutic targets. Moderna will fund the programs and upon identifying suitable targets, it will take responsibility for the development, manufacturing, and commercialization.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.